Author

A. Antoranz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Bioengineering· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 6 Research Focus:differential expression· 5 Organism:human· 5 Assay:scRNA-seq· 3 Approach:statistical model· 3 Approach:deep learning· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2

Frequent Co-Authors

F. M. Bosisio· 4 shared Y. van Herck· 4 shared D. Lambrechts· 3 shared O. Bechter· 3 shared V. Boecxstaens· 3 shared A. Bassez· 2 shared E. Landeloos· 2 shared G. Bervoets· 2 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

F. M. Bosisio

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

NK cells contribute to resistance to anti-PD1 therapy in immune-excluded melanomas

E. Landeloos, J. Pozniak, N. Roda, A. de Visscher, A. Antoranz, Y. van Herck, G. Bervoets, F. M. Bosisio, V. Boecxstaens, A. Bassez, D. Lambrechts, P. Matthys, O. Bechter, J.-C. Marine

The paper identifies NK cells as contributors to resistance to anti-PD1 therapy in immune-excluded melanomas using single-cell RNA sequencing and spatial proteomics.

bioRxiv · Dec 14, 2023 · PreprintCancer Biology

A TCF4/BRD4-dependent regulatory network confers cross-resistance to targeted and immune checkpoint therapy in melanoma

J. Pozniak, D. Pedri, E. Landeloos, Y. Van Herck, A. Antoranz, P. Karras, A. Nowosad, S. Makhzami, G. Bervoets, M. Dewaele, L. Vanwynsberghe, S. Cinque, S. Kint, K. Vandereyken, T. Voet, , J.-C. Marine

This study identifies a TCF4/BRD4-dependent regulatory network that drives cross-resistance to ICB and targeted therapy in melanoma by analyzing scRNA-seq data from a longitudinal cohort.

bioRxiv · Aug 11, 2022 · PreprintCancer Biology

A fully defined pluripotent stem cell derived multi-liver-cell model for steatohepatitis and fibrosis

M. K. Gautam, B. Toprakhisar, M. Van Haele, A. Antoranz, R. Boon, F. Chesnais, J. De Smedt, T. I. Idoype, M. Canella, P. Tilliole, J. De Boeck, T. Tricot, M. Bajaj, A. Ranga, F. M. Bosisio, , C. M. Verfaillie

The paper develops a co-culture system of pluripotent stem cell-derived liver cells to model NASH-induced steatosis, inflammation, and fibrosis.

bioRxiv · Sep 3, 2020Bioengineering

A Pan-Cancer Blueprint of the Heterogeneous Tumour Microenvironment Revealed by Single-Cell Profiling

J. Qian, S. Olbrecht, B. Boeckx, H. Vos, D. Laoui, E. Etlioglu, E. Wauters, V. Pomella, S. Verbandt, P. Busschaert, A. Bassez, A. Franken, M. Vanden Bempt, J. Xiong, B. Weynand, , D. Lambrechts

This study profiles single cells from multiple cancer types to create a pan-cancer blueprint of stromal cell heterogeneity, identifying shared and unique cell populations and their characteristics.

bioRxiv · Apr 1, 2020Cancer Biology

Functional heterogeneity of lymphocytic patterns in primary melanoma dissected through single-cell multiplexing.

F. M. Bosisio, A. Antoranz, M. M. Bolognesi, L. Marcelis, C. Chinello, J. Wouters, F. Magni, L. Alexopoulos, G. Cattoretti, J. van den Oord, Y. Van Herck, O. Bechter, M. Stas, V. Boecxstaens

The paper characterizes immune heterogeneity in primary melanoma using single-cell multiplex analysis, revealing functional subcategories of lymphocytic patterns and their prognostic significance.

bioRxiv · Nov 7, 2019 · PreprintCancer Biology

A functional landscape of chronic kidney disease entities from public transcriptomic data

F. Tajti, C. Kuppe, A. Antoranz, M. M. Ibrahim, H. Kim, F. Ceccarelli, C. Holland, H. Olauson, J. Floege, L. G. Alexopoulos, R. Kramann, J. Saez-Rodriguez

This paper integrates transcriptomic data from nine CKD entities to delineate their molecular differences and identify potential therapeutic targets.

bioRxiv · Feb 21, 2019Pathology